Figures
Abstract
Objective
The present study aimed to explore the hypothesis that bile salt-stimulated lipase (BSSL), in addition to being a key enzyme in dietary fat digestion during early infancy, plays an important role in inflammation, notably arthritis.
Methods
Collagen-induced arthritis (CIA) and pristane-induced arthritis (PIA) in rodents are commonly used experimental models that reproduce many of the pathogenic mechanisms of human rheumatoid arthritis, i.e. increased cellular infiltration, synovial hyperplasia, pannus formation, and erosion of cartilage and bone in the distal joints. We used the CIA model to compare the response in BSSL wild type (BSSL-WT) mice with BSSL-deficient ‘knock-out’ (BSSL-KO) and BSSL-heterozygous (BSSL-HET) littermates. We also investigated if intraperitoneal injection of BSSL-neutralizing antibodies affected the development or severity of CIA and PIA in mice and rats, respectively.
Results
In two consecutive studies, we found that BSSL-KO male mice, in contrast to BSSL-WT littermates, were significantly protected from developing arthritis. We also found that BSSL-HET mice were less prone to develop disease compared to BSSL-WT mice, but not as resistant as BSSL-KO mice, suggesting a gene-dose effect. Moreover, we found that BSSL-neutralizing antibody injection reduced both the incidence and severity of CIA and PIA in rodents.
Citation: Lindquist S, Andersson E-L, Lundberg L, Hernell O (2012) Bile Salt-Stimulated Lipase Plays an Unexpected Role in Arthritis Development in Rodents. PLoS ONE 7(10): e47006. https://doi.org/10.1371/journal.pone.0047006
Editor: Oliver Frey, University Hospital Jena, Germany
Received: March 29, 2012; Accepted: September 10, 2012; Published: October 11, 2012
Copyright: © Lindquist et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was provided by the Swedish Research Council/Medicine, Swedish Orphan Biovitrum AB, Västerbotten County Council (ALF), the Oscar foundation, and Umeå Biotech Incubator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have the following interests: Patent application: “New method for treatment of inflammatory diseases” (PCT/SE2010/050377). Inventors: Olle Hernell, Susanne Lindquist, Lennart Lundberg. The authors have received funding from Swedish Orphan Biovitrum AB (unconditional grant). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Introduction
Collagen-induced arthritis (CIA) in mice is a commonly used experimental model that reproduces many of the pathogenic features of human rheumatoid arthritis (RA), i.e. increased infiltration of neutrophilic granulocytes, synovial hyperplasia, pannus formation, and erosion of cartilage and bone in the distal joints. In the present study we used the CIA model to test the hypothesis that bile salt-stimulated lipase (BSSL), also termed carboxyl ester lipase or bile salt-dependent lipase, is a key component of inflammation, including chronic arthritis. BSSL is primarily recognized as a lipolytic enzyme that facilitates digestion and absorption of dietary fat. It has broad specificity and hydrolyzes a variety of different substrates [1]–[3]. BSSL is expressed in the exocrine pancreas and secreted into the intestinal lumen in all species thus far investigated, including those devoid of pancreatic triglyceride lipase [4], [5]. Besides BSSL an oncofetal variant termed feto-acinar pancreatic protein (FAPP), has been described. This form is poorly secreted and exclusively expressed in human fetal and diseased pancreas, but to our knowledge not in other species, or in pancreas of healthy adults [6].
In some species, including humans, BSSL is also expressed by the lactating mammary gland and secreted in milk. Milk-derived BSSL contributes significantly to the efficient utilization of milk fat in breastfed infants [7], [8]. In fact, together with pancreatic lipase related protein 2, BSSL is the key enzyme in neonatal intestinal fat digestion [9]–[11].
BSSL may also have effects beyond the gastrointestinal tract. It is present in the blood [12], but so far the source of circulating BSSL is uncertain. While it has been suggested that circulating BSSL originates in the pancreas and reaches the intravascular space via intestinal absorption and passage through the arterial wall [13], some authors suggest that BSSL is expressed and secreted by macrophages [14] and endothelial cells [15]. Contrasting to the view that BSSL is absorbed by the intestine, we and others have shown that neither does serum levels of BSSL increase after a meal of breast milk, nor do serum levels of BSSL in breastfed and formula-fed human infants differ, even though breast milk is the major source of BSSL in the breastfed newborn but is absent from formula [16], [17]. With respect to function, some argue that circulating BSSL influences lipoprotein metabolism, chylomicron assembly and secretion, reverse cholesterol transport, and modulates atherosclerosis [2], [18]–[20]. We showed that BSSL prevents binding of HIV-1 to its receptor on dendritic cells in vitro, and thereby inhibits HIV-1 transfer to CD4+ T-cells [21], [22]. BSSL was also found to be stored in platelets and released upon their activation, suggesting a role in thrombus formation [23]. In the latter study, released BSSL was proposed to interact with the chemokine receptor CXCR4 on platelets to enhance platelet aggregation and thrombus formation. Recently, we discovered that BSSL is expressed by polymorphonuclear granulocytes present in human liver biopsies and in circulating granulocytes collected from healthy volunteers (Lindquist et al., unpublished). Collectively these observations suggested that BSSL could be a common denominator in inflammation and thus play an important role in the inflammatory process.
We here report that BSSL deficient mice are significantly less prone to develop disease in the CIA model compared to wild type littermates. Moreover, we show that administration of BSSL neutralizing antibodies suppresses the course of disease in CIA mice and also in pristane induced arthritis (PIA) in rats, another commonly used RA model [24].
Materials and Methods
Experimental animals
Female DBA/1 mice, aged 10–12 weeks at arrival, were purchased from Taconic Europe (Ejby, Denmark). DBA/1 mice are widely used for CIA studies and although male DBA/1 mice may be slightly more susceptible to develop arthritis compared to female DBA/1 mice, we used females for therapeutic trials. The advantage being that females can be randomly mixed in cages during experiments, while males tend to fight if they are put together.
Male Dark Agouti (DA) rats, aged 8–10 weeks at arrival, were purchased from Harlan Laboratories Europe (Horst, The Netherlands). BSSL knock-out (BSSL-KO) mice of C57BL/6J background have been described previously [25] and were a kind gift from Dr. J. Breslow, Rockefeller University, New York. To obtain susceptibility to CIA, conferred by the major histocompatibility complex (MHC) Aq haplotype [26], BSSL-KO mice were crossed to mouse strain C57BL/10Q (obtained from the Medical Inflammation Research, Lund University, Lund, Sweden) initially for one generation. BSSL heterozygous (BSSL-HET) F1 offspring were then inter-crossed to generate BSSL-KO and BSSL wild type (BSSL-WT) littermates that were further screened and selected as either homozygous or heterozygous for the MHC Aq allele. The mice included in the first CIA experiment were 13 BSSL-KO/Aq homozygous (9 males, four females), 23 BSSL-KO/Aq heterozygous (8 males, 15 females), 12 BSSL-WT/Aq homozygous (8 males, four females) and 16 BSSL-WT/Aq heterozygous (8 males, 8 females). All experiments were performed on littermates to exclude nonlinked genetic effects. After the initial CIA experiment, the BSSL-KO allele was backcrossed to mouse strain C57BL/10Q for seven generations. BSSL-HET/MHC Aq homozygous mice were then inter-crossed to generate BSSL-KO, BSSL-HET and BSSL-WT littermates that were used in following CIA experiment. Screening of BSSL genotypes was performed by polymerase chain reaction (PCR) as previously described [25] and MHC genotyping was performed using microsatellite marker D17mit230 [27].
All mice and rats were bred or kept at 12 h light/dark cycles in polystyrene cages containing wood shavings and were fed with standard rodent chow and water ad libitum at the common animal facilities of Umeå University, Umeå (mice) or Biomedical Centre, Lund University, Lund (rats).
Ethics Statement
Mice experiments were approved by the Umeå ethical committee (permission Nos. A61-08 and A103-10) and rat experiments were approved by the Malmö/Lund ethical committee (permission No. M107-07).
Collagen-induced arthritis
CIA was induced in mice according to standard protocol [28]. In short, mice were immunized by subcutaneous (s.c.) injection at the base of the tail with 100 µg rat collagen type II (CII), prepared as described [29], or chick CII (Chondrex, Inc. Redmond, WA, USA), each emulsified in an equal volume of complete Freund's adjuvant (CFA; Sigma-Aldrich, St. Louis, MO, USA) at a final concentration of 2 mg/ml. After 21 days, mice were boosted by injection near the first injection site with 50 µg rat or chick CII emulsified in equal volume of incomplete Freund's adjuvant (IFA; Sigma-Aldrich) at final concentration of 1 mg/ml. Severity of disease was followed by clinical scoring every second or third day, starting one week before boost.
Clinical evaluation of arthritis
Development of arthritis was evaluated using a macroscopic scoring system based on the number of inflamed joints (defined by swelling and redness of the joint) in each paw. Each inflamed digit and knuckle scores 1 point each, whereas an inflamed wrist or ankle scores 5 points, resulting in a maximum score of 15 for each paw and 60 for each mouse [30]. To avoid cage-depending variation, mice or rats of different genotypes or from different treatment groups were always randomly mixed in cages during the experiments. The examiner was blinded to BSSL genotypes or treatment group during scoring.
Pristane-induced arthritis
PIA was induced in rats as previously described [24], [31]. In brief, DA rats, known to have a high susceptibility for developing PIA, were given a single s.c. injection of 150 µl pristane (Acros Organics, Geel, Belgium) at the base of the tail. Development of disease (arthritis severity) was followed by clinical scoring every second to third day as described above.
Antibodies
Monospecific rabbit anti-mouse BSSL antibodies (CDV15) were developed by Agrisera AB (Vännäs, Sweden). The CDV15 antibodies were raised in rabbits by immunization with a synthetic peptide corresponding to amino acid 328–341 in the mature mouse protein [32]. Polyclonal anti-peptide 328–341 antibodies were purified from serum using a peptide affinity column obtained from Agrisera AB according to the suppliers' protocol. Normal rabbit IgG (purified on protein G sepharose) was obtained from Agrisera AB. CDV15 antibodies and normal rabbit IgG were diluted in phosphate-buffered saline (PBS; Gibco-Invitrogen, Carlsbad, CA, USA) and passed through a 0.45 µm sterile filter before use.
Western blot analysis
Pieces of pancreatic tissue obtained from mice and rats were homogenized in APBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.0) containing 1 Mini Complete tablet per 10 ml (Roche Diagnostics, Mannheim, Germany). The homogenate was centrifuged at 14,000 rpm for 10 min and the supernatant was collected. All steps were performed at 4°C to minimize the risk of proteolysis. Approximately 30 µg of total protein was separated on 12% SDS- polyacrylamide gel electrophoresis according to Laemmli [33] and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA). Western blotting was carried out using the ECL Advance Western Blotting Detection Kit, following the manufacturer's recommendations (GE Healthcare). The CDV15 antibody was used as primary antibody, and a peroxidase-conjugated donkey-anti-rabbit IgG (DAKO, Glostrup, Denmark) was used as secondary antibody.
Treatment of collagen-induced arthritic mice with BSSL neutralizing antibodies
Seventy-five female DBA/1 mice (Taconic, 12 weeks of age) were randomized to five groups of 15 mice each for treatment. CIA was induced in all mice by an injection of chick CII at day 0 and a booster dose given on day 21. Every fourth day, beginning the day before boost (day 20), each group was given an intraperitoneal (i.p.) injection (0.2 ml total volume) with one of the following: 0.1 mg CDV15 antibody, 0.2 mg CDV15 antibody, 0.1 mg normal rabbit IgG, 0.2 mg normal rabbit IgG, or PBS (Gibco). Development of disease (arthritis severity) was followed by clinical scoring every fourth day, starting at day 20.
Treatment of pristane-induced arthritic rats with BSSL neutralizing antibodies
Forty DA rats were injected with pristane to induce arthritis at day 0. The rats were randomized to one of four groups of 10 animals each for treatment. At day 5, 10, and 15 the rats were treated by i.p. injection (1 ml) with one of the following; anti-BSSL 1 mg/kg, anti-BSSL 5 mg/kg, etanercept (Enbrel, Wyeth, Great Britain) 1 mg/kg, or PBS (Gibco). Development of disease (arthritis severity) was followed by clinical scoring daily or every second day as described above, starting on day 8.
Plasma anti-CII antibody concentration
The antibody response against rat CII in plasma was determined using enzyme-linked immunosorbent assay (ELISA) as described [34]. Briefly, 96-well plates (Costar, Cambridge, MA, USA) were coated overnight at 4°C with 50 µl per well of 10 µg/ml rat CII in PBS. All washes were performed with PBS (pH 7.4) containing 0.1% Tween-20. Plasma was diluted in PBS and analyzed in duplicates. The amount of bound IgG antibody was estimated after incubation with biotin-conjugated isotype-specific antibodies (Southern Biotechnology Associates, Inc. Birmingham, AL, USA) followed by Extravidin-Peroxidase (Sigma) and developed with ABTS (Roche Diagnostics GmbH, Mannheim, Germany) as substrate followed by detection in a Spectra Max at OD 405 nm (Molecular Devices, Sunnyvale, CA, USA).
Plasma cartilage oligomeric matrix protein concentration
Plasma concentration of cartilage oligomeric matrix protein (COMP) was determined by competitive ELISA as described [35]. Briefly, rat COMP was used for coating of the microtiter plates and for preparing the standard curve included on each plate. Plates were blocked with 1% bovine serum albumin (BSA) in PBS for 2 hours at room temperature. After blocking, plasma co-incubated with rabbit polyclonal antiserum against rat COMP was added and the plates were incubated for 2 hours at room temperature. The amount of plasma COMP was estimated after incubation with an alkaline phosphatase-conjugated swine-anti-rabbit isotype-specific antibody (DAKO, Glostrup, Denmark) and phosphatase substrate (Sigma Aldrich) followed by detection in a Spectra Max (Molecular Devices) at OD 405 nm.
Histological examination
Hind limbs were removed from representative animals after the animals were killed at study termination. The samples were fixed in 4% phosphate buffered paraformaldehyde for 24 hours, decalcified in 1% EDTA solution, and embedded in paraffin. All samples were sectioned and stained with hematoxylin and eosin at Histo-Center AB (Göteborg, Sweden).
Statistical analyses
Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). The Mann-Whitney U test (exact routine) was used to compare mean arthritis scores and serum concentrations of COMP, anti-CII antibody, and anti-rabbit IgG between BSSL-KO versus BSSL-WT mice. To compare mean arthritis scores and anti-rabbit IgG concentrations between multiple groups of mice, the Kruskal-Wallis exact test was used; in case of an overall significant difference, pair wise Mann-Whitney U tests were subsequently performed. Derived p-values were then adjusted for multiple testing (Bonferroni correction). Fisher's exact test was used to compare the cumulative incidence of arthritis between BSSL-KO and BSSL-WT mice, or between multiple groups of mice. In the latter case, derived p-values were adjusted for multiple testing. Adjusted p-values of <0.05 were considered statistically significant.
Results
BSSL deficient mice are resistant to collagen induced arthritis
The susceptibility of BSSL-KO mice (17 males and 19 females, age 8–11 weeks) to develop CIA was compared to that of BSSL-WT littermates (16 males and 12 females) and immediately a distinct gender-based difference was found. The most striking result was detected in BSSL deficient male mice, which were almost completely protected from arthritis, and consequently developed significantly lower mean arthritis scores compared to their BSSL-WT male littermates (p<0.01 from day 28 onwards; Fig. 1A). The proportion (cumulative incidence) of animals that developed disease (arthritis score≥1) was also significantly lower in BSSL-KO compared to BSSL-WT male mice (p<0.01 from day 28 onwards; Fig. 1B). At study discontinuation (day 57), only 6 of 17 BSSL-KO male mice (35%) had developed any clinical sign of arthritis, and of these only one had reached an arthritis score>5. In contrast, 14 of 16 BSSL-WT male mice (88%) had developed disease and 13 had reached an arthritis score>5.
Littermates of BSSL-KO and BSSL-WT mice were immunized with rat collagen type II (CII) on day 0 and boosted on day 21. Arthritis development was followed by blinded clinical scoring 2–3 times per week for 57 days after the initial CII injection. Mean clinical score of arthritis severity in (A) male mice and (C) female mice and the cumulative incidence of arthritis presented as percentage of affected mice with clinical score≥1 in (B) male mice and (D) female mice are shown. Error bars indicate ± SEM. ????? = p<0.05; ??? = p<0.01; ??? = p<0.001.
In contrast to results obtained with male mice, both the BSSL-KO and the BSSL-WT female mice were highly resistant to CIA and showed consistently low mean arthritis scores (Fig. 1C). Furthermore, the proportion (cumulative incidence) of mice that developed disease (arthritis score≥1) was significantly lower in both BSSL-KO and BSSL-WT female mice compared to BSSL-WT male mice (Fig. 1D). Only four of 12 BSSL-WT (33%) and three of 18 BSSL-KO female mice (17%) showed clinical signs of arthritis at day 57. However, all four diseased BSSL-WT female mice but none of the BSSL-KO female mice had an arthritis score>5 at that point.
Concentrations of IgG anti-CII antibody and COMP, as markers of cartilage degradation, were determined in plasma collected on experimental days 30 and 57 (COMP only at day 57). There was no significant difference in antibody response against CII between BSSL-KO and BSSL-WT mice, with no gender differences (Fig. 2A, B). In contrast, significantly lower COMP levels were found in plasma obtained from male BSSL-KO mice compared to male BSSL-WT mice on experimental day 57 (p<0.001; Fig. 2C). Plasma levels of COMP in BSSL-KO and BSSL-WT females were low and comparable to the level found in BSSL-KO male mice.
Littermates of BSSL-KO and BSSL-WT mice were immunized with rat CII on day 0 and boosted on day 21 to induce arthritis. The concentration of IgG anti-CII antibody in plasma was determined by ELISA at (A) day 30 and (B) day 57 after initial injection with rat CII. As a marker of cartilage degradation, the concentration of cartilage oligomeric matrix protein (COMP) present in mouse plasma was determined by ELISA (C) on day 57 after initial injection with rat CII. Values are expressed as mean ± SEM. ??? = p<0.001.
To further evaluate arthritis severity, paraffin sections of hind limb ankle joints from five BSSL-WT and five BSSL-KO representative animals were stained with hematoxylin and eosin. A clear association between inflammation score and increased cell infiltration in the joint synovium and cartilage destruction of diseased mice, compared to mice without clinical signs of disease, was observed (Fig. 3).
Hematoxylin and eosin staining of hind limb sections from (A) BSSL-KO and (B) BSSL-WT mice taken at day 57 after initial injection with rat CII. The joint of BSSL-KO mice has normal histological appearance without cellular infiltration whereas the joint of BSSL-WT mice shows signs of cartilage destruction and significant inflammatory cell infiltration. Images shown are representative of those obtained from five mice in each group. Original magnification ×4.
A follow-up study, using essentially the same experimental protocol as above comprised of 13 BSSL-KO, 15 BSSL-WT, and 16 BSSL-HET littermate male mice (age 8–14 weeks), was conducted. The only deviations from the first study protocol were that the mice had been backcrossed to mouse strain C57BL/10Q for seven generations to exclude nonlinked genetic effects and that chick CII, instead of rat CII, was used to induce arthritis. Arthritis scores in this follow-up study were consistent with the previous results obtained for male mice, i.e. BSSL-KO mice developed significantly lower mean arthritis scores compared to their BSSL-WT littermates (p<0.05 on day 35, 49, 52 and 58; Fig. 4A). Furthermore, there was a trend for protection of BSSL-HET mice from developing disease compared to BSSL-WT mice, but they were not as resistant as BSSL-KO mice and the difference between BSSL-HET and BSSL-WT did not reach statistical significance (Fig. 4A). Not only the severity but also the proportion (cumulative incidence) of mice that developed disease (arthritis score≥1) was significantly lower in BSSL-KO compared to BSSL-WT mice (p<0.05 on day 49, 52 and 58; Fig. 4B). It should be noted that the cumulative incidence of disease was also significantly lower in BSSL-KO mice compared to BSSL-HET mice (p<0.05 on day 45 onwards) but after adjusting for multiple testing, these differences did not remain statistically significant. However, at study discontinuation only 3 of 12 BSSL-KO mice (25%) had an arthritis score≥1 compared to 10 of 16 BSSL-HET (62%) and 12 of 15 BSSL-WT littermates (80%).
Littermates of male BSSL-KO (n = 13), BSSL-WT (n = 15), and BSSL-HET (n = 16) mice were immunized with chick CII on day 0 and boosted on day 21. Arthritis development was followed by blinded clinical scoring 2–3 times per week for 58 days after initial CII injection. (A) Mean clinical score of arthritis severity and (B) cumulative incidence of arthritis (percentage of affected mice with clinical score≥1) are shown. Error bars indicate ± SEM. ??? = p<0.05.
BSSL neutralizing antibodies significantly inhibit development of arthritis in mice and rats
The hypothesis that targeting BSSL with neutralizing antibodies could affect development or severity of CIA was investigated in 75 female DBA/1 mice, randomized to one of five groups (n = 15 per group) for treatment. Two different doses of the anti-BSSL antibody CDV15 were compared to the same doses of normal rabbit IgG and PBS as placebo control. Arthritis was induced in all mice at day 0 and treatment was given as i.p. injections every fourth day, starting the day before boost (day 20). Compared to the placebo control, treatment with 0.1 mg of CDV15 significantly prevented or mitigated development of arthritis at least until the seventh and last dose was given on day 44 (p<0.05 from day 40 onwards if not adjusted for multiple testing; Fig. 5A). Treatment with 0.1 mg normal rabbit IgG also tended to alleviate disease, though less effectively than CDV15. Increasing the dose of CDV15 from 0.1 mg to 0.2 mg per injection did not improve the preventive effect of CDV15 on disease development. In fact, at the time of discontinuation of the study (day 50) the 0.2 mg group showed a mean arthritis score similar to the 0.2 mg normal rabbit IgG and PBS placebo control groups. At day 40 after the initial CII immunization, the relative number of mice that had developed disease (arthritis score≥1) tended to be lower in the group treated with 0.1 mg CDV15 compared to all other groups, although the differences were not statistically significant (p>0.05; Fig. 5B). Nor did the effect obtained by treatment with CDV15 (0.1 mg per injection) on decreased arthritis severity (Fig. 5A) remain statistically significant after adjusting for multiple testing.
Seventy-five DBA/1 female mice were immunized with chick CII in CFA on day 0 and boosted with CII in IFA at day 21. Mice were randomized to one of five groups of 15 animals each, which, beginning on day 20, were treated every fourth day until day 44 with one of the following: 0.1 mg CDV15 antibody, 0.2 mg CDV15 antibody, 0.1 mg normal rabbit IgG, 0.2 mg normal rabbit IgG, or PBS (placebo control). Arthritis development and severity was followed by clinical scoring 2–3 times per week for 50 days after initial CII injection. (A) Mean score of arthritis severity and (B) cumulative incidence of arthritis (percentage of affected mice with clinical score≥1) are shown. (C) At the time of discontinuation (day 50) the concentration of mouse anti-rabbit IgG was determined in plasma collected from all animals. Error bars indicate ± SEM. For clarity, error bars were omitted in (A). ??? = p<0.05; ??? = p<0.01.
To test if the decline in treatment effect seen after the seventh dose of 0.1 mg CDV15 and if the lack of improved efficacy by increasing the CDV15 dose from 0.1 mg to 0.2 mg could be an immunological response to CDV15 resulting in anti-antibody production, the concentration of mouse anti-rabbit IgG was determined in plasma collected from all animals at the time of study discontinuation. Indeed, significantly increased anti-rabbit IgG plasma concentrations were found in the groups treated with 0.1 mg CDV15 and 0.2 mg CDV15 compared to the PBS control group (p<0.01) and to the 0.1 mg normal rabbit IgG group (p<0.05; Fig. 5C).
The postulated capacity of BSSL neutralizing antibodies to prevent arthritis was further investigated in arthritic rats. To provide support for the rationale of using the CDV15 antibody in rats we first checked for cross-reactivity of CDV15 with rat BSSL by Western blot. Results showed that although the deduced amino acid sequence of rat BSSL differs at three positions compared to the synthetic peptide used to develop CDV15 antibodies, CDV15 reacted with BSSL present in crude extracts of both mouse and rat pancreas (Fig. 6).
Crude extracts derived from three rat pancreata (lane 1–3) and three mouse pancreata (lane 4–6) were separated by SDS-PAGE (12%), transferred to PVDF membranes, and probed with the CDV15 antibody. Partial degradation of the BSSL protein has occurred in lanes 2 and 3. 67 kDa indicates the mass of mouse and rat pancreatic BSSL.
Forty male DA rats (age 8–10 weeks), randomized to one of four groups (n = 10 per group) for treatment, were given a single injection of pristane, known to induce arthritis within two weeks [24]. Treatment was given as i.p. injections (1 ml) on days 5, 10, and 15 after pristane immunization. Two different doses of CDV15 antibody were tested (1 mg/kg and 5 mg/kg) and the effect was compared to treatment with etanercept (1 mg/kg) or PBS as placebo control. Clinical scoring showed that although the incidence of disease development (arthritis score≥1) was 100% in all groups (data not shown), treatment with CDV15 anti-BSSL antibodies at the higher dose (5 mg/kg per injection) significantly reduced disease severity as compared to both etanercept and PBS (p<0.05 from day 17 onwards; Fig. 7A). Additionally, the group receiving the lower dose of CDV15 (1 mg/kg per injection) showed a clear tendency towards amelioration, supporting a dose-dependent preventive effect. The protective effect of anti-BSSL treatment on the clinical severity of arthritis was confirmed by histological examination. Treated animals showed a marked decrease in the number of inflammatory cells present in the joint synovium and less cartilage destruction (data not shown).
DA male rats were immunized with pristane on day 0 to induce arthritis. Rats were randomized to receive different treatments on three separate occasions (day 5, 10, and 15) as follows: (A) Four groups of rats (n = 10 each) were treated with i.p. injection of either CDV15 antibody 1 mg/kg, CDV15 antibody 5 mg/kg, etanercept 1 mg/kg, or PBS (placebo control). (B) Three groups of rats (n = 10 each) were treated with one of the following: i.p. injection of CDV15 antibody 5 mg/kg, s.c. injection of CDV15 antibody 5 mg/kg, or PBS (i.p. injection). Arthritis development was followed by clinical scoring 2–3 times per week for 23 or 24 days after initial pristine injection. Mean scores of arthritis severity are shown. Error bars indicate ± SEM. ??? = p<0.05; ??? = p<0.01; ??? = p<0.001.
To verify the results obtained by injecting anti-BSSL CDV15 antibody during PIA in rats and at the same time compare different routes for treatment, a follow-up study using essentially the same experimental protocol as above was conducted. Thirty male DA rats (age 8–10 weeks) were randomized into three groups (n = 10 per group) for treatment. CDV15 antibody (5 mg/kg) was injected either i.p. or s.c. on days 5, 10, and 15 after pristane immunization and the effect was compared to i.p. PBS as placebo control. Clinical scoring confirmed previous results and showed that regardless of injection route, treatment with CDV15 anti-BSSL antibody (5 mg/kg per injection) significantly reduced disease severity as compared to PBS (p<0.05 from day 15 onwards; Fig. 7B).
Discussion
Novel observations presented here strongly support our hypothesis that vascular BSSL, originating in neutrophils and platelets, affects inflammatory conditions such as chronic arthritis. We applied the CIA model and in two consecutive studies demonstrated that BSSL-KO mice, in contrast to BSSL-WT littermates, were significantly protected from developing inflammatory arthritis defined by swelling and redness of the paw joints. BSSL-KO mice developed arthritis at a lower incidence and reduced severity compared to BSSL-WT littermates. We also showed that BSSL-HET mice were less prone to develop disease as compared to BSSL-WT mice, but they were not as resistant as BSSL-KO mice, suggesting a gene-dose effect. In one of the studies we noticed a gender-based difference when only four of 12 female BSSL-WT mice (33%) compared to 14 of 16 male BSSL-WT mice (88%) developed disease. This was not surprising, since it is well known that males are more often affected than females in the CIA mouse model [36]. Results from clinical scoring were confirmed by histological evaluation. Sections of hind limbs obtained from diseased mice showed massive infiltration of inflammatory cells in the joint synovium and cartilage destruction. These features were not detected in samples collected from mice without clinical signs of disease.
It should be noted that BSSL-KO mice show normal growth and development and, besides impaired intestinal absorption of esterified cholesterol due to the enzyme's cholesteryl ester hydrolyzing activity [37], adult mice do not suffer from increased morbidity [25], [38], [39]. So far, the only reported notable negative phenotype associated with BSSL deficiency is restricted to newborn BSSL-KO pups, which exhibit significantly reduced capacity to digest dietary milk fat compared to BSSL-WT pups. As a result, lipid droplets accumulate in the distal small intestine and injure the villus epithelium [40]. However, this is a transient phenotype that disappears during the suckling-weaning transition as expression of pancreatic lipase and phospholipase A2, the two major enzymes responsible for intestinal digestion of dietary fat in adults, increase and thus compensate for the lack of BSSL [9], [41].
Currently, we can only speculate on the mechanism through which BSSL influences the inflammatory process. As there was no difference between BSSL-KO and BSSL-WT mice in the CIA model with respect to anti-CII IgG levels it is unlikely that BSSL affects B cell activity. Since BSSL, as already mentioned, is proposed to interact with CXCR4 on platelets [23], one appealing possibility is that BSSL is involved in recruitment of inflammatory cells via CXCR4 and its ligand chemokine stromal cell-derived factor 1 (SDF-1, also termed CXCL12). Very recently, BSSL was identified as a marker for HIV-1 progression to AIDS and emergence of CXCR4-using viruses in HIV-1 infected patients. Furthermore, an association between BSSL genotypes and CD4 cell count in blood of uninfected individuals was reported [42]. Several studies suggest that the SDF-1/CXCR4 axis plays a central role in the pathogenesis of RA by triggering migration and recruitment of leukocytes, activated T cells, and plasmacytoid dendritic cells into the inflamed joints [43]–[47]. Cxcr4 and Cxcl12 null-knockout mice are embryonic lethal [48], [49] but studies using T cell-specific CXCR4-deficient mice showed that CXCR4 expression in T cells is important for the development of CIA by recruiting activated T cells toward inflammatory sites [46]. In patients with RA the frequency of CXCR4 expressing synovial tissue CD4+ memory T cells is elevated compared with normal controls [50] and the concentration of SDF-1 in synovial fluid is significantly increased [51].
Previous studies found that treatment with AMD3100, a specific CXCR4 antagonist, significantly reduced the severity of CIA in mice [43], [44]. AMD3100 was further shown to inhibit the chemotactic effect of SDF-1 on splenocytes in vitro as well as migration of leukocytes into SDF-1 containing subcutaneous air pouches in vivo [44]. In the present study we found evidence that BSSL-neutralizing antibodies significantly reduced the incidence and severity of CIA and PIA in mice and rats, respectively. The unexpected reverse dose-response effect in the mouse CIA experiment could be explained by an immunological response to CDV15 resulting in anti-antibody production towards rabbit IgG. This was confirmed by higher anti-rabbit IgG levels in the IgG treated groups compared to the PBS control group. It seems reasonably that a more pronounced difference between groups (0.1 mg vs. 0.2 mg) had been observed had the evaluation been made before the effect started to decrease at day 44 in the CDV15 0.1 mg group.
In contrast to AMD3100 it is unlikely that BSSL antagonizes SDF-1/CXCR4 signaling. We rather hypothesize that BSSL interferes with the interaction of SDF-1 with CXCR4 and thus triggers the signaling pathway leading to migration and recruitment of inflammatory cells to the site of acute inflammation. This could initially be a positive role for BSSL, but when the inflammation is no longer controlled and becomes “chronic”, BSSL may sustain the inflammatory response and hence become a negative factor and a target for treatment of inflammatory disease.
Taken together, the present data support a key role for BSSL in the inflammatory process, at least in rodents. In the future, more studies are warranted to explore the exact mechanism by which BSSL is involved in the inflammatory process, and whether a BSSL-neutralizing agent could serve as a therapeutic model to reduce the inflammatory response in humans as well.
Acknowledgments
We are grateful to Drs. Peter Olofsson and Malin Hultqvist, Redoxis AB, Sweden, for fruitful discussions and valuable advice during the animal studies, professor Torgny Stigbrand for helpful discussions regarding antibodies and immunoreactions, and associate professor Hans Stenlund for advice on statistical procedures. We would also like to thank Sofia Kapsi for excellent technical assistance.
Author Contributions
Conceived and designed the experiments: SL ELA LL OH. Performed the experiments: SL ELA. Analyzed the data: SL LL OH. Wrote the paper: SL LL OH.
References
- 1. Blackberg L, Hernell O (1983) Further characterization of the bile salt-stimulated lipase in human milk. FEBS Lett 157: 337–341.
- 2. Hui DY, Howles PN (2002) Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res 43: 2017–2030.
- 3. Nyberg L, Farooqi A, Blackberg L, Duan RD, Nilsson A, et al. (1998) Digestion of ceramide by human milk bile salt-stimulated lipase. J Pediatr Gastroenterol Nutr 27: 560–567.
- 4. Gjellesvik DR, Lombardo D, Walther BT (1992) Pancreatic bile salt dependent lipase from cod (Gadus morhua): purification and properties. Biochim Biophys Acta 1124: 123–134.
- 5. Patton JS, Warner TG, Benson AA (1977) Partial characterization of the bile salt-dependent triacylglycerol lipase from the leopard shark pancreas. Biochim Biophys Acta 486: 322–330.
- 6. Mas E, Crotte C, Lecestre D, Michalski JC, Escribano MJ, et al. (1997) The oncofetal J28 epitope involves fucosylated O-linked oligosaccharide structures of the fetoacinar pancreatic protein. Glycobiology 7: 745–752.
- 7. Andersson Y, Savman K, Blackberg L, Hernell O (2007) Pasteurization of mother's own milk reduces fat absorption and growth in preterm infants. Acta Paediatr 96: 1445–1449.
- 8. Lindquist S, Hernell O (2010) Lipid digestion and absorption in early life: an update. Curr Opin Clin Nutr Metab Care 13: 314–320.
- 9. Li X, Lindquist S, Lowe M, Noppa L, Hernell O (2007) Bile salt-stimulated lipase and pancreatic lipase-related protein 2 are the dominating lipases in neonatal fat digestion in mice and rats. Pediatr Res 62: 537–541.
- 10. Miller R, Lowe ME (2008) Carboxyl ester lipase from either mother's milk or the pancreas is required for efficient dietary triglyceride digestion in suckling mice. J Nutr 138: 927–930.
- 11. Xiao X, Mukherjee A, Ross LE, Lowe ME (2011) Pancreatic lipase-related protein-2 (PLRP2) can contribute to dietary fat digestion in human newborns. J Biol Chem 286: 26353–26363.
- 12. Blind PJ, Blackberg L, Hernell O, Ljungberg B (1987) Carboxylic ester hydrolase: a serum marker of acute pancreatitis. Pancreas 2: 597–603.
- 13. Bruneau N, Bendayan M, Gingras D, Ghitescu L, Levy E, et al. (2003) Circulating bile salt-dependent lipase originates from the pancreas via intestinal transcytosis. Gastroenterology 124: 470–480.
- 14. Kodvawala A, Ghering AB, Davidson WS, Hui DY (2005) Carboxyl ester lipase expression in macrophages increases cholesteryl ester accumulation and promotes atherosclerosis. J Biol Chem 280: 38592–38598.
- 15. Li F, Hui DY (1998) Synthesis and secretion of the pancreatic-type carboxyl ester lipase by human endothelial cells. Biochem J 329 (Pt 3) 675–679.
- 16. Blackberg L, Blind PJ, Ljungberg B, Hernell O (1985) On the source of bile salt-stimulated lipase in human milk: a study based on serum concentrations as determined by sandwich enzyme-linked immunosorbent assay technique. J Pediatr Gastroenterol Nutr 4: 441–445.
- 17. Shamir R, Nganga A, Berkowitz D, Diamond E, Lischinsky S, et al. (2003) Serum levels of bile salt-stimulated lipase and breast feeding. J Pediatr Endocrinol Metab 16: 1289–1294.
- 18. Camarota LM, Woollett LA, Howles PN (2011) Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout mice. FASEB J 25: 1370–1377.
- 19. Kirby RJ, Zheng S, Tso P, Howles PN, Hui DY (2002) Bile salt-stimulated carboxyl ester lipase influences lipoprotein assembly and secretion in intestine: a process mediated via ceramide hydrolysis. J Biol Chem 277: 4104–4109.
- 20. Shamir R, Johnson WJ, Morlock-Fitzpatrick K, Zolfaghari R, Li L, et al. (1996) Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro. J Clin Invest 97: 1696–1704.
- 21. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, et al. (2006) Bile Salt-Stimulated Lipase from Human Milk Binds DC-SIGN and Inhibits Human Immunodeficiency Virus Type 1 Transfer to CD4+ T Cells. Antimicrob Agents Chemother 50: 3367–3374.
- 22. Stax MJ, Naarding MA, Tanck MW, Lindquist S, Hernell O, et al. (2011) Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One 6: e17316.
- 23. Panicot-Dubois L, Thomas GM, Furie BC, Furie B, Lombardo D, et al. (2007) Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 117: 3708–3719.
- 24. Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, et al. (1996) Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol 149: 1675–1683.
- 25. Weng W, Li L, van Bennekum AM, Potter SH, Harrison EH, et al. (1999) Intestinal absorption of dietary cholesteryl ester is decreased but retinyl ester absorption is normal in carboxyl ester lipase knockout mice. Biochemistry 38: 4143–4149.
- 26. Wooley PH, Luthra HS, Stuart JM, David CS (1981) Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 154: 688–700.
- 27. Jirholt J, Cook A, Emahazion T, Sundvall M, Jansson L, et al. (1998) Genetic linkage analysis of collagen-induced arthritis in the mouse. Eur J Immunol 28: 3321–3328.
- 28. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283: 666–668.
- 29. Smith BD, Martin GR, Miller EJ, Dorfman A, Swarm R (1975) Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys 166: 181–186.
- 30.
Holmdahl R, Carlsen S, Mikulowska A, Vestberg M, Brunsberg U, et al.. (1998) Genetic analysis of murine models for rheumatoid arthritis. In: Adolpho K, editor. New York: CRC press. pp. 215–238.
- 31. Olofsson P, Holmdahl R (2007) Pristane-induced arthritis in the rat. Methods Mol Med 136: 255–268.
- 32. Lidmer AS, Kannius M, Lundberg L, Bjursell G, Nilsson J (1995) Molecular cloning and characterization of the mouse carboxyl ester lipase gene and evidence for expression in the lactating mammary gland. Genomics 29: 115–122.
- 33. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
- 34. Holmdahl R, Klareskog L, Andersson M, Hansen C (1986) High antibody response to autologous type II collagen is restricted to H-2q. Immunogenetics 24: 84–89.
- 35. Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31: 583–591.
- 36. Holmdahl R, Jansson L, Gullberg D, Rubin K, Forsberg PO, et al. (1985) Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol 62: 639–646.
- 37. Falt H, Hernell O, Blackberg L (2002) Does bile salt-stimulated lipase affect cholesterol uptake when bound to rat intestinal mucosa in vitro? Pediatr Res 52: 509–515.
- 38. Howles PN, Carter CP, Hui DY (1996) Dietary free and esterified cholesterol absorption in cholesterol esterase (bile salt-stimulated lipase) gene-targeted mice. J Biol Chem 271: 7196–7202.
- 39. Vesterhus M, Raeder H, Kurpad AJ, Kawamori D, Molven A, et al. (2010) Pancreatic function in carboxyl-ester lipase knockout mice. Pancreatology 10: 467–476.
- 40. Howles PN, Stemmerman GN, Fenoglio-Preiser CM, Hui DY (1999) Carboxyl ester lipase activity in milk prevents fat-derived intestinal injury in neonatal mice. Am J Physiol 277: G653–661.
- 41. Gilham D, Labonte ED, Rojas JC, Jandacek RJ, Howles PN, et al. (2007) Carboxyl ester lipase deficiency exacerbates dietary lipid absorption abnormalities and resistance to diet-induced obesity in pancreatic triglyceride lipase knockout mice. J Biol Chem 282: 24642–24649.
- 42. Stax MJ, Kootstra NA, van 't Wout AB, Tanck MW, Bakker M, et al. (2012) HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism. PLoS One 7: e32534.
- 43. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, et al. (2001) AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 167: 4686–4692.
- 44. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, et al. (2005) Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 7: R1208–1220.
- 45. Lande R, Giacomini E, Serafini B, Rosicarelli B, Sebastiani GD, et al. (2004) Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol 173: 2815–2824.
- 46. Chung SH, Seki K, Choi BI, Kimura KB, Ito A, et al. (2010) CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Res Ther 12: R188.
- 47. Kumar A, Humphreys TD, Kremer KN, Bramati PS, Bradfield L, et al. (2006) CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 25: 213–224.
- 48. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382: 635–638.
- 49. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595–599.
- 50. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, et al. (2000) Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165: 6590–6598.
- 51. Kanbe K, Takagishi K, Chen Q (2002) Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 46: 130–137.